Skip to main content

This job has expired

You will need to login before you can apply for a job.

Principal Scientist, Potency Assay Development

Employer
Intellia Therapeutics
Location
Cambridge, MA, United States
Start date
Oct 16, 2020

View more

Discipline
Science/R&D, Bio-Assay Development, Biotechnology
Required Education
Associate Degree
Position Type
Full time
Hotbed
Genetown

Job Details

Our mission:

Developing curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

At Intellia, we are committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to create novel engineered cell therapies for immuno-oncological and autoimmune diseases.

Intellia is seeking a motivated Potency Principal Scientist/Group Leader to join our quickly growing Analytical Development team. The primary responsibilities for this position will focus on development, troubleshooting, and qualification/validation of cell-based bioassays and immunoassays, as well as the development of internal analytical capabilities to support in house process development. The successful candidate will have expertise in developing functional cell-based assays for use in evaluating the relative potency of drug substance and drug product.

Responsibilities:
    • Independently design, develop, optimize, qualify and/or validate and transfer novel cell-based bioassays and immunoassays for potency
    • Draft and review SOPs, technical reports, and regulatory documents
    • Supervise and mentor laboratory research associates and scientists
    • Represent the Analytical Development function on matrixed CMC and other development teams
    • Transfer analytical methods internally or to contract laboratories; manage internal experiments and trend internal method performance and specifications
    • Lead bioassay comparability testing to support process changes and transfers
    • Data review, approval, analysis, graphing, reporting and presentation to internal and external audiences, including regulatory agencies
    • Act as a technical resource in investigations, health authority inquiries and regulatory filings
    • Maintain current knowledge of the field and area(s) of scientific expertise and development
    • Assess method performance and identify issues and propose and implement appropriate remediation in conjunction with QA and company policies
    • Familiarity with statistical concepts and design of experiments (DoE) related to functional cell-based assay development, optimization, and validation


Qualifications:
    • Ph.D. in Biochemistry, Cell Biology, or a related field with 5 or more years of experience in an industrial setting
    • Experience working in a regulated pharmaceutical industry setting
    • Gene and/or cell therapy experience preferred
    • Extensive hands-on experience with the design, development, optimization, qualification and validation of novel bioassays and immunoassays across multiple platforms and technologies (e.g, ELISA, MSD, flow cytometry and cell based - proliferation, phosphorylation, reporter and cytotoxicity assays)
    • Knowledge of GMP as relevant to laboratory practices in sample handling and analysis of GLP and GMP samples
    • Knowledge of industry USP/ICH guidances for the development, qualification/ validation of functional cell-based assays and potency methods
    • High competence in common software and data analysis packages (e.g., PLA software, SoftMax Pro, GraphPad Prism, JMP, Microsoft Office tools)
    • Excellent organizational, documentation, and communication skills; adaptive learning, critical thinking, and the ability to work well in a team


#LI-KO1

What Intellia Stands For:

We push boundaries. We are focused on positively disrupting health care treatment of patients with genomic diseases. The values we live by and drivers we look for are:

- One is respect for individuals; our unique qualities and strengths; our own ways to understand, learn and improve. One is our single-minded determination to excel; to succeed together. One is you and us - trusting and counting on every single one of us.

- Explore because we seek new ways to tackle disease. Explore with unbounded minds...free from assumptions, open to ideas. Explore by staying curious, by pushing boundaries, overcoming obstacles. Explore means thinking of new ways.

- Disrupt by thinking courageously...and creating a better future. Disrupt by defying conformity; interrogating the status quo; questioning our momentum. Disrupt with challenging thoughts...with that breed of skepticism that shows you have better solutions.

- Deliver with your focus on the objective and your determination to complete the task. Deliver by advancing relentlessly and by maintaining high standards...even when nobody is watching. Deliver by staying accountable and pulling your weight. Deliver because patients are counting on us to make the promise reality. Get it done.

POSITION: Full-Time, Exempt

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Intellia's web-based application process is managed through Lever. Information submitted through application forms is collected by Lever and subject to Lever's privacy policy .

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert